RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

December 6, 2025 2:00 PM EST

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI®

Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI® is used earlier in the treatment journey

Eighty percent of as-treated patients in CARTITUDE-4 with standard-risk cytogenetics remained progression-free and off treatment at 30 months after a single infusion of CARVYKTI®

Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D... More